FDA sent out a MedWatch warning, on July 12, 2013, after Medtronic recalled its MiniMed Paradigm insulin infusion sets.
FDA sent out a MedWatch warning, on July 12, 2013, after Medtronic recalled its MiniMed Paradigm insulin infusion sets.
Medtronic sent an Urgent Medicinal Device Safety Notification to all Paradigm insulin pump users and distributors to alert them that certain lots have the potential for over or under delivery of insulin. “If insulin or other fluids come in contact with the inside of the tubing connector, this can result in too much or too little insulin being delivered, resulting in hypoglycemia or hyperglycemia, which can be severe and lead to serious illness,” the MedWatch warning said.
The recalled products were manufactured from October 2001 through June 2013 and distributed from December 2001 through June 2013.
If patients notice anything unusual during the infusion set prime process, such as the insulin continuing to drip from the tip of the infusion set cannula when priming has been completed, this may indicate that the connector vents are not working properly, according to FDA. “If this occurs, do not insert the infusion set and immediately call the HelpLine at 1-888-204-7616 for assistance,” FDA stated.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More